





Highlights

 **Pancreatic Cancer White Paper launched.** On the 15th September the **European Alliance for Personalised Medicine (EAPM)** in collaboration with **EUPancreas COST Action (WG4)** launched the White Paper during the WG4 training school in Aegina, Greece. The White Paper is a direct appeal to policymakers, legislators, and regulators to encourage innovation, to enhance prevention, and to broaden access to treatment. It also calls on all stakeholders to work more closely together to reduce the burden of pancreatic cancer on patients and on society. Click on the link provided in the press release (posted at www.eupancreas.com) to read the full text of this paper.

 **Aegina WG4 Training School (Genomics and Genetics).** The Training school was held during 10-15th September in Aegina, Greece, jointly with CHIP-ME Cost Action. Several lectures of public-private partnership challenges in pancreatic cancer research and policy were given by a panel of experts in these issues, including various members of WG4. Among the issues raised were the need to address research funding shortfalls on PDAC, to join efforts in developing tools for personalised medicine, or to break the current gaps between research & policy. A summary of the sessions, along with the presentations, is provided in our website www.eupancreas.com.

 **PancreOs (Pancreatic Cancer Overall Survival Registry).** A pilot study of PancreOs has started in Spain. A meeting with the ENCR and the Spanish network of population-based cancer registries will be held on the 5th October to seek the most suitable way of retrieving reliable PDAC survival data in Spain and in Europe (next phase).

 **The Annual Conference, MC/WG meetings and workshop on "Burning issues in pancreatology"** will be held during 5-7 November 2015 in Cluj-Napoca, Romania. More information is available at: eupancreas.com/meetings-events & pancreas2015.webs.com

 **A new organisation** has joined EUPancreas. We welcome Pancreatic Cancer UK!

 **Twitter:** [EUPancreas](https://twitter.com/EUPancreas) has 96 followers! Become a follower of EUPancreas in twitter if you have not done yet.



PANCREATIC CANCER WHITE PAPER 2015

Deadly 'silent' cancer needs a voice in EU research and investment

Aegina, Greece



This White paper has been supported by members of the COST Action (BM1204) 'An integrated European platform for pancreatic cancer research: from basic science to clinical and public health interventions for a rare disease.'

It has been facilitated by the European Alliance for Personalised Medicine.

COST Actions BM1204 & IS1303 AEGINA SUMMER SCHOOL Aegina Island, Greece – 10-14 September 2015



Theme:

Genomics and Genetics:
Current developments and controversies



EFISDS & EPC Combined Meeting 2015
EUPancreas Annual Conference 2015

"Burning issues in Pancreatology"



Early Career Investigators (ECIs):


 Awardees of the **5th CALL FOR SHORT-TERM SCIENTIFIC MISSIONS (STSMs)** will be published this week. Keep an eye at www.eupancreas.com/training

Upcoming Scientific Events:

 **25-29 September 2015:** ECCO/ESMO congress. Viena, Austria


 **24-28 October 2015:** UEG week. Barcelona, Spain

 **5-7 November 2015:** EUPancreas Annual Conference, meetings and workshop. Cluj-Napoca, Romania.


 **10 November 2015:** 3rd meeting of the EU-Multi-Stakeholder platform on Pancreatic cancer. Brussels, Belgium.


 **13 November 2014:** **WORLD PANCREATIC CANCER DAY**


The "COST Action BM1204 EUPancreas" has been acknowledged in:

 Mocchi E, et al. PanGen-Fam: Spanish registry of hereditary pancreatic cancer. Eur J Cancer 2015 Jul 23.

Some Pancreatic Cancer-related published studies:

 Ducreux, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015 Sep;26 Suppl 5:v56-v68.

 Hurwitz, et al. Randomized double-blind phase II study of Ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol 2015 Sep 8.

 Nitsche U, et al. Resectability after first-line FOLFIRINOX in initially unresectable locally advanced pancreatic cancer: a single center experience. Ann Surg Oncol 2015 Sep 8.